Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL15270535 | 1.00 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL8672233 | 1.00 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL29691 | 1.00 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL19128314 | 0.95 | CA2 (0.39) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL2407345 | 0.94 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL7820 | 0.94 | — | — | |
| SCHEMBL10527922 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL15467677 | 0.89 | — | — | |
| SCHEMBL5447474 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Hydrogen Sulfide SCHEMBL8062675 | 0.89 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289414-A1 | TISSUE PROTECTIVE HYDROGEL | ETH Zürich (CH) | 2023-12-13 | — | — | EP | claimed |
| US-11077133-B2 | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes | THOMAS JEFFERSON UNIVERSITY (US) | 2021-08-03 | — | — | US | claimed |
| US-20200197435-A1 | Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes | UNIV JEFFERSON (US) | 2020-06-25 | — | — | US | claimed |
| US-10543226-B2 | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes | THOMAS JEFFERSON UNIVERSITY (US) | 2020-01-28 | — | — | US | claimed |
| WO-2015162130-A1 | BASE-MODIFIED-NUCLEOSIDE ANALOGS FOR THE DETECTION OF O6-ALKYL GUANINE | ETH ZURICH (CH) | 2015-10-29 | — | — | WO | claimed |
| US-20140066491-A1 | CHEMICAL MODIFICATION MOTIFS FOR MIRNA INHIBITORS AND MIMETICS | MIRAGEN THERAPEUTICS (US) | 2014-03-06 | — | — | US | claimed |
| CN-102803284-A | Chemical modification motifs for miRNA inhibitors and mimetics | MIRAGEN THERAPEUTICS | 2012-11-28 | — | — | CN | claimed |
| US-20120148664-A1 | CHEMICAL MODIFICATIONS MOTIFS FOR MIRNA INHIBITORS AND MIMETICS | MIRAGEN THERAPEUTICS (US) | 2012-06-14 | — | — | US | claimed |
| EP-2440566-A1 | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS | Miragen Therapeutics (US) | 2012-04-18 | — | — | EP | claimed |
| WO-2010144485-A1 | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS | MIRAGEN THERAPEUTICS (US) | 2010-12-16 | — | — | WO | claimed |
| EP-4378531-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | Thomas Jefferson University (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024077130-A1 | METHODS AND COMPOSITIONS FOR TREATING BLADDER CANCER | THOMAS JEFFERSON UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240100078-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | UNIV JEFFERSON (US) | 2024-03-28 | — | — | US | disclosed |
| EP-3592841-B1 | COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | UNIV JEFFERSON (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4289414-A1 | TISSUE PROTECTIVE HYDROGEL | ETH Zürich (CH) | 2023-12-13 | — | — | EP | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
| US-5554746-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5519134-A | ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-21 | — | — | US | disclosed |
| WO-1995018792-A1 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148664-A1 | CHEMICAL MODIFICATIONS MOTIFS FOR MIRNA INHIBITORS AND MIMETICS | RNMT, NSUN2, NSUN3 | CA2 4819/4885SLC34A1 3331/4885KDM4E 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.